DOCSLIB.ORG

The Adnexal Mass and Early Ovarian Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Adnexal Mass and Early Ovarian Cancer TheThe AdnAdneexxaall MassMass andand EarlyEarly OOvarianvarian CanCanccerer FredFred UelanUelandd,, MMDD UniversiUniversityty ofof KentucKentuckkyy GynGynecolecoloogicgic OncolOncolooggyy ““NeveNeverr givegive in.in. NNeverever givegive in.in. NeveNeverr,, neveneverr,, nnever,ever, nevernever-- inin nothinothinngg greatgreat oror smsmallall,, larglargee oror petpetttyy-- nevernever givegive in,in, exexceceptpt toto convictionsconvictions ooff hohonnoror andand goodgood sense.sense.”” Sir Winston Churchill OvarianOvarian TTuumorsmors WhoWho Cares?Cares? Surgical costs exceed $5,000,000,000 annually 144 million women in USA – 5-10% will undergo a surgical procedure for a suspected ovarian neoplasm during their lifetime 30 million women over age 50 – 17% develop cystic ovarian tumors – 2 million have persistent tumors RiskRisk ofof MalMaliignancygnancy ManagManageemmentent chalchalllengeenge isis anan accuaccurratatee riskrisk ofof malignanmalignanccyy aasssseesssmsment.ent. RiskRisk ofof malignanmalignanccyy withinwithin anan ovarovariaiann neoplaneoplasmsm varivarieess wwithith age:age: – 10% in children – 15% in reproductive age women – 50% in postmenopausal women OvarianOvarian TTuumorsmors PremenPremenoopaupausasall WomenWomen NonNon--inflinflaammmmatoratoryy ovarianovarian ttumumorsors – 70% functional cysts – 20% neoplastic – 10% endometriomas 15%15% ofof oovarianvarian neoplaneoplasmsmss inin reproductivereproductive ageage wwomomeenn aarree mamalignantlignant OtherOther – Inflammatory process, bowel OvarianOvarian TTuumorsmors PremenPremenoopaupausasall WomenWomen FunctionalFunctional cystscysts – < 8 cm – Unilateral – Simple, unilocular on TVS – No ascites InitialInitial reprepeeatat TTVSVS 66--88 weeksweeks OCPsOCPs dodo notnot incrincreeasease likelihoodlikelihood ofof resolution,resolution, butbut mamayy dedeccrereaasese riskrisk ofof recurrecurrrenceence OvarianOvarian TTuumorsmors Spanos W. Am J Obstet Gynecol 1973 Type of Cyst # of Patients % Regressed under observation 205 72 Required exploratory laparotomy 81 28 Ovarian neoplasms 46 16 Benign epithelial 32 11 Benign teratoma 9 3 Malignant epithelial 4 1.4 Dysgerminoma 1 0.3 Endometriosis 28 10 Para-ovarian cyst 4 1.4 Hydrosalpinx 3 1 Functional cysts 0 0 OvarianOvarian TTuumorsmors Modesitt et al, Gyn Oncol 2003 SpontaneousSpontaneous ResoResollutioutionn 22612261 (69%)(69%) CystCyst ++ SSepteptuumm 537537 (17%)(17%) PersistentPersistent CCysystt 220220 (7%)(7%) CystCyst +Solid+Solid aarreeaa 168168 (5%)(5%) SolidSolid MasMasss 2121 (0.6%)(0.6%) RRememovedoved byby unreunrellatedated surgesurgeryry 4040 (1.2%)(1.2%) 3,2593,259 EndometriEndometrioomama MucinousMucinous CystadenomCystadenomaa MatureMature CCysystticic TeratomaTeratoma OvarianOvarian DyDyssgerminomagerminoma OvarianOvarian TTuumorsmors PostmenoPostmenoppauaussalal WomenWomen BenignBenign epithelialepithelial ttuumomorr StrStromomalal ttuumormor – Granulosa cell – Fibroma – Thecoma EpithelialEpithelial cancanccerer MetMetaastatistaticc cancanccerer OvarianOvarian TTuumorsmors PostmenoPostmenoppauaussalal WomenWomen 50%50% mmalignantalignant AsAsyymptmptoommatiaticc ssiimmpleple cyscystt << 1010 ccmm wwithith nonormrmalal CCAA--125125 – serial TVS “Any“Any ovarianovarian ttuummoror inin aa pospostmtmenopenopaausalusal wwomomanan thatthat doedoess notnot mmeeeett thethe aboveabove critercriteriiaa shouldshould bebe assassumumeded toto bebe mamalignant”lignant” – Antiquated? SerousSerous OOvvaarianrian CancerCancer WhoWho GGetsets RReeferredferred toto aa CCaancnceerr SpecSpeciialist?alist? BenefitsBenefits ofof SurgicalSurgical Staging?Staging? PatientsPatients inin whwhomom cocompmprrehensiveehensive surgicalsurgical stagingstaging conficonfirrmsms eearlarlyy--stagestage disdiseeasasee havehave aa betterbetter prognosisprognosis tthhanan thosethose whowho wweerree thouthougghtht toto havehave eeaarlyrly ssttageage disdiseeasease bbutut werweree unstagedunstaged AccuraAccurattee identificidentificaationtion ofof wwoomenmen wwhhoo requirerequire adjuvantadjuvant cchheemothmotheerapyrapy AppropriateAppropriate StagingStaging WWomomeenn withwith earearlyly stagestage ovarianovarian ccancerancer – N=291 CCoomplemplettee surgisurgiccalal staging:staging: – 97% gynecologic oncologists – 52% general obstetrician/gynecologists – 35% general surgeons McGowan L, et al. Obstet Gynecol 1985;65:568-72. ReferralReferral PaPattternsterns Utah Cancer Registry: 848 new ovarian cancers diagnosed 1992-1998 Only 39% were ever seen by a Gyn Onc Patients with advanced disease had significant survival advantage when managed by Gyn Onc (median survival 26 mo vs. 15 mo, p < 0.01) Age < 40, age > 70, and residence in a rural area were not seen by a gynecologic oncologist Carney ME, et al. Gynecol Oncol 2002;84:36-42. ValueValue ofof SpSpeecialcialiistssts Meta-analysis (18 studies) concluded marked benefit with Gynecologic Oncologist (Giede 2005) – Complete surgical staging with early stage disease – Optimal cytoreductive surgery with advanced disease – Improved median and overall survival Others supporting GO involvement: – NCCN guidelines – SGO, ACOG – SOGC clinical practice guidelines – NIH consensus statement – London Medical Advisory statement SuggestiveSuggestive ofof MalignancyMalignancy ACACOOG,G, SSGGOO ExExamaminationination – Fixed or nodular ImImagingaging studystudy – Mostly solid tumor or distant mets – Ascites CACA--125125 – premenopausal > 200 – postmenopausal > 35 Im et. al. Obstet Gynecol , 2005 SoSo HHooww DoDo II KnowKnow WhoWho GGetsets ReferReferrreded aanndd WhoWho DoDoeesn’sn’tt?? ExExamaminationination ImImagingaging SerSerumum PelvicPelvic ExExamaminationination PelvicPelvic ExExamaminationination InaccuraInaccuracycy Patient age ≥ 55 – 30% Patient weight ≥ 200 lb – 9% Uterine weight ≥ 200 g – 16% Ueland et al, Gyn Oncol 2005 SoSo HHooww DoDo II KnowKnow WhoWho GGetsets ReferReferrreded aanndd WhoWho DoDoeesn’sn’tt?? ExExamaminationination ImImagingaging SerSerumum PelvicPelvic ExExamam vs.vs. UltrasoundUltrasound Pelvic Exam Ultrasound P value Patient age 0.30 0.74 < 0.001 ≥ 55 Patient wt 0.09 0.73 < 0.001 ≥ 200 lb Uterine wt 0.16 0.80 < 0.001 ≥ 200 g Ueland et al, Gyn Oncol 2005 UltrasoundUltrasound DifferentiatDifferentiatiingng OvarianOvarian TumorsTumors Author Number Prevalence Sens(%) Spec (%) PPV(%) PPV (at 20%) Kobayashi, 1976 406 15 70 73 31 39 Hermann, 1987 241 21 82 93 75 73 Finkler, 1988 102 36 62 95 88 75 Benacerraf, 1990 100 30 80 87 72 62 Granberg, 1990 180 22 82 92 74 73 Sassone, 1991 143 10 100 83 37 59 Ueland, 2003 442 12 98 81 41 56 *Definition of (+) US varied with each author SonogSonogrraphaphiicc ChChaaractracteeristristicicss OvarianOvarian TumorsTumors Benign Malignant Unilateral Bilateral Simple (MI < 5) Complex (MI ≥ 5) Doppler – Partly solid – PI > 1.0, RI > 0.4 – Internal papillations – Peripheral flow Doppler No ascites – PI < 1.0, RI < 0.4 – Central flow Resolution Ascites Persistence or growth KentuckyKentucky MMorphologyorphology IInndexdex Ueland et al Gyn Oncol 2003 UK gynecologic ultrasound database 442 women with confirmed ovarian tumor – Morphology Indexing – Color Flow Doppler – Surgery TumorTumor StruStrucctureture ScoreScore == 00 TumorTumor StruStrucctureture ScoreScore == 33 TumorTumor StruStrucctureture ScoreScore == 55 MorphologyMorphology IndexIndex TotalTotal ScoreScore (0(0--4)4) 100 90 80 70 60 50 % Benign 40 % Cancer 30 20 10 0 0 1 2 3 4 MorphologyMorphology IndexIndex TotalTotal ScoreScore (5(5--10)10) 100 90 92 80 83 70 77 60 50 % Benign 40 % Cancer 38 30 32 20 20 10 0 5 6 7 8 9 10 KentuckyKentucky MMorphologyorphology IInndexdex MIMI << 55 benignbenign MIMI ≥≥ 55 mamalignantlignant KentuckyKentucky MMorphologyorphology IInndexdex SensitivitySensitivity 0.9810.981 SpecificitSpecificityy 0.8070.807 PositivePositive predictivepredictive valuevalue 0.4090.409 NegativeNegative predictipredictivvee valuvaluee 0.9970.997 AccurAccuraaccyy 0.8280.828 Disease Prevalence = 12% WhatWhat aboutabout Doppler?Doppler? DopplerDoppler Sens Spec PPV NPV MI 0.981 0.807 0.409 0.997 PI < 1.00 0.528 0.776 0.288 0.905 RI < 0.4 0.222 0.867 0.222 0.867 No flow 0.163 0.640 0.056 0.854 f0 = transmitted US frequency v cos θ = target velocity c = velocity of surrounding medium TVSTVS probeprobe θθ vesselvessel ∆∆ff == 2f2f0 vv (cos(cos θθ)) // cc DopplerDoppler RReeproducibilitproducibilityy ∆∆ff == 2f2f0vv (cos(cos θθ)) // cc IsIs thethe angleangle ofof insonationinsonation constantconstant ((θθ))?? – 2 to 3 fold change for ∆ θ (from 30°-80°)* – Optimal angle and frequency depends on depth of vessel IsIs eeaachch DopplerDoppler mmeasureasureemmentent ofof thethe ssameame vessel?vessel? AreAre thesthesee vesselsvessels ststrraighaightt?? *J Vasc Surg 1990; 11:688-94 UltrasoundUltrasound ConclusionConclusionss 1. MIMI ≥≥ 55 40% malignant 2. MIMI << 55 0.3% malignant 3. DopplerDoppler addsadds littllittlee OtherOther IImagingmaging CTCT scanscan abdabdomomenen andand pelvispelvis – IV and PO contrast – CT-guided biopsy Accuracy exceeds 90% for solid tumors What about high risk cystic tumors? MRIMRI PETPET CTCT ScanScan Omental cake Ovarian tumor SoSo HHooww DoDo II KnowKnow WhoWho GGetsets ReferReferrreded aanndd WhoWho DoDoeesn’sn’tt?? ExExamaminationination ImImagingaging SerSerumum CACA--125125 Antigen derived from: – coelomic epithelium (pericardium, pleura, peritoneum) – mullerian epithelium (tubal, endometrial, endocervical) Two different assays – Assay I < 35 U/ml – Assay II < 20 U/ml Expressed by 80%
Load more

Recommended publications
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • Pure Choriocarcinoma of the Ovary: a Case Report
    Case Report J Gynecol Oncol Vol. 22, No. 2:135-139 pISSN 2005-0380 DOI:10.3802/jgo.2011.22.2.135 eISSN 2005-0399 Pure choriocarcinoma of the ovary: a case report Lin Lv1, Kaixuan Yang2, Hai Wu1, Jiangyan Lou1, Zhilan Peng1 Departments of 1Obstetrics and Gynecology and 2Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China Pure ovarian choriocarcinomas are extremely rare and aggressive tumors which are gestational or non­gestational in origin. Due to the rarity of the tumor, there is a lack of information on the clinicopathologic features, diagnosis, and treatment. We report a case of a pure ovarian choriocarcinoma, likely of non­gestational origin, treated by cytoreductive surgery in combination with post­operative chemotherapy. The patient was free of disease after a 12­month follow­up. Keywords: Choriocarcinoma, Non­gestational, Ovary INTRODUCTION CASE REPORT Pure ovarian choriocarcinomas are extremely rare malignan­ A 48­year­old woman was admitted to our department cies which are of gestational or non­gestational in origin. with a 6­month history of irregular vaginal bleeding and a The gestational type may arise from an ectopic ovarian pre­ 1­month history of a palpable abdominal mass. She had a gnancy or present as a metastasis from a uterine or tubal nor mal vaginal delivery at 26 years of age and had no recent choriocarcinoma, while the non­gestational type is a rare history of normal pregnancies, molar gestations, or abortions. germ cell tumor with trophoblastic differentiation. The esti­ The physical examination revealed abdominal tenderness and mated incidence of gestational ovarian choriocarcinomas a fixed mass arising from the pelvis to 3 cm below the um­ is 1 in 369 million pregnancies [1].
    [Show full text]
  • Imaging in Gynecology: What Is Appropriate Francisco A
    Imaging in Gynecology: What is Appropriate Francisco A. Quiroz, MD Appropriate • Right or suitable • To set apart for a specific use Appropriateness • The quality or state for being especially suitable or fitting 1 Imaging Modalities Ultrasound Pelvis • Trans abdominal • Transvaginal Doppler 3-D • Hysterosonogram Computed Tomography MR PET Practice Guidelines Describe recommended conduct in specific areas of clinical practice. They are based on analysis of current literature, expert opinion, open forum commentary and informal consensus Consensus Conference National Institutes of Health (NIH) U.S. Preventive Services Task Force Centers for Disease Control (CDC) National Comprehensive Cancer Network (NCCN) American College of Physicians American College of Radiology Specialty Societies 2 Methodology Steps in consensus development ? • Formulation of the question or topic selection • Panel composition – requirements • Literature review • Assessment of scientific evidence or critical appraisal • Presentation and discussion • Drafting of document • Recommendations for future research • Peer review • Statement document • Publication – Dissemination • Periodic review and updating ACR Appropriateness Criteria Evidence based guidance to assist referring physicians and other providers in making the most appropriate imaging or treatment decision for a specific clinical condition 3 Appropriateness Criteria Expert panels • Diagnostic imaging • Medical specialty organizations American Congress of Obstetricians and Gynecologists
    [Show full text]
  • What Is New on Ovarian Carcinoma
    diagnostics Review What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors Antonio De Leo 1,2,3,*,† , Donatella Santini 3,4,† , Claudio Ceccarelli 1,3, Giacomo Santandrea 5 , Andrea Palicelli 5 , Giorgia Acquaviva 1,2, Federico Chiarucci 1,2 , Francesca Rosini 4, Gloria Ravegnini 3,6 , Annalisa Pession 2,6, Daniela Turchetti 3,7, Claudio Zamagni 8, Anna Myriam Perrone 3,9 , Pierandrea De Iaco 3,9, Giovanni Tallini 1,2,3,‡ and Dario de Biase 2,3,6,‡ 1 Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum—University of Bologna, Via Massarenti 9, 40138 Bologna, Italy; [email protected] (C.C.); [email protected] (G.A.); [email protected] (F.C.); [email protected] (G.T.) 2 Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero—Universitaria di Bologna/Azienda USL di Bologna, 40138 Bologna, Italy; [email protected] (A.P.); [email protected] (D.d.B.) 3 Centro di Studio e Ricerca delle Neoplasie Ginecologiche, Alma Mater Studiorum—University of Bologna, 40138 Bologna, Italy; [email protected] (D.S.); [email protected] (G.R.); [email protected] (D.T.); [email protected] (A.M.P.); [email protected] (P.D.I.) 4 Pathology Unit, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy; [email protected] 5 Citation: De Leo, A.; Santini, D.; Pathology Unit, AUSL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy; Ceccarelli, C.; Santandrea, G.; [email protected] (G.S.); [email protected] (A.P.) 6 Palicelli, A.; Acquaviva, G.; Chiarucci, Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy 7 Unit of Medical Genetics, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Via Massarenti 9, F.; Rosini, F.; Ravegnini, G.; Pession, 40138 Bologna, Italy A.; et al.
    [Show full text]
  • American Family Physician Web Site At
    Diagnosis and Management of Adnexal Masses VANESSA GIVENS, MD; GREGG MITCHELL, MD; CAROLYN HARRAWAY-SMITH, MD; AVINASH REDDY, MD; and DAVID L. MANESS, DO, MSS, University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee Adnexal masses represent a spectrum of conditions from gynecologic and nongynecologic sources. They may be benign or malignant. The initial detection and evaluation of an adnexal mass requires a high index of suspicion, a thorough history and physical examination, and careful attention to subtle historical clues. Timely, appropriate labo- ratory and radiographic studies are required. The most common symptoms reported by women with ovarian cancer are pelvic or abdominal pain; increased abdominal size; bloating; urinary urgency, frequency, or incontinence; early satiety; difficulty eating; and weight loss. These vague symptoms are present for months in up to 93 percent of patients with ovarian cancer. Any of these symptoms occurring daily for more than two weeks, or with failure to respond to appropriate therapy warrant further evaluation. Transvaginal ultrasonography remains the standard for evaluation of adnexal masses. Findings suggestive of malignancy in an adnexal mass include a solid component, thick septations (greater than 2 to 3 mm), bilaterality, Doppler flow to the solid component of the mass, and presence of ascites. Fam- ily physicians can manage many nonmalignant adnexal masses; however, prepubescent girls and postmenopausal women with an adnexal mass should be referred to a gynecologist or gynecologic oncologist for further treatment. All women, regardless of menopausal status, should be referred if they have evidence of metastatic disease, ascites, a complex mass, an adnexal mass greater than 10 cm, or any mass that persists longer than 12 weeks.
    [Show full text]
  • Pseudocarcinomatous Hyperplasia of the Fallopian Tube Mimicking Tubal
    Lee et al. Journal of Ovarian Research (2016) 9:79 DOI 10.1186/s13048-016-0288-x CASE REPORT Open Access Pseudocarcinomatous hyperplasia of the fallopian tube mimicking tubal cancer: a radiological and pathological diagnostic challenge Nam Kyung Lee1,2†, Kyung Un Choi3†, Ga Jin Han1, Byung Su Kwon4, Yong Jung Song4, Dong Soo Suh4 and Ki Hyung Kim2,4* Abstract Background: Pseudocarcinomatous hyperplasia of the fallopian tube is a rare, benign disease characterized by florid epithelial hyperplasia. Case presentation: The authors present the history and details of a 22-year-old woman with bilateral pelvic masses and a highly elevated serum CA-125 level (1,056 U/ml). Ultrasonography and magnetic resonance imaging (MRI) of the pelvis showed bilateral adnexal complex cystic masses with a fusiform or sausage-like shape. Contrast-enhanced fat-suppressed T1-weighted images showed enhancement of papillary projections of the right adnexal mass and enhancement of an irregular thick wall on the left adnexal mass, suggestive of tubal cancer. Based on MRI and laboratory findings, laparotomy was performed under a putative preoperative diagnosis of tubal cancer. The final pathologic diagnosis was pseudocarcinomatous hyperplasia of tubal epithelium associated with acute and chronic salpingitis in both tubes. Conclusion: The authors report a rare case of pseudocarcinomatous hyperplasia of the fallopian tubes mimicking tubal cancer. Keywords: Pseudocarcinomatous hyperplasia of the fallopian tube, Tubal cancer, Pelvic mass Background mitotic activity related to estrogenic stimulation might Various benign conditions of the female genital tract be observed in the tubal epithelium, but florid or atyp- may be confused with malignant neoplasms.
    [Show full text]
  • Endometrioid Carcinoma of the Ovary and Uterus – Synchronous Primaries Pathology S Ection Or Metastasis: a Case Report
    Case Report ection Endometrioid Carcinoma of the Ovary S and Uterus – Synchronous Primaries Pathology or Metastasis: A Case Report ESWARI V., GEETHA PRAKASH, IRFAN A. ANSARI, BHANUMATHY V., GOMATHI PALVANNANATHAN ABSTRACT showed well differentiated endometrioid ovarian cancer and well Synchronous endometrioid carcinoma of the uterine corpus differentiated endometrioid endometrial cancer with squamous and ovary is an uncommon but well known phenomenon. Such differentiation and metastasis of the endometrial cancer to the cases may represent either two primary tumours or a single cervix. Patients with synchronous endometroid tumours of the primary and associated metastasis. There are significant clinical endometrium and ovary are generally younger,tend to be of low implications with either diagnosis. We present a case of a 48 grade and the prognosis of endometrioid type carcinoma is better year old unmarried women who came to our hospital with Right than other histological types of carcinoma. Immunohistochemistry ovarian mass measuring 13cm. Total abdominal hysterectomy with plays an important role to differentiate single primary with metastasis bilateral salphingoopherectomy was done. Histological examination and dual primaries especially at places with limited resources. Key Words: Synchronous primaries, ovarian cancer, Endometrial cancer INTRODUCTION The simultaneous development of multiple primary cancers in the upper female genital tract is a well known phenomenon. Of these the commonest is the endometrioid carcinoma of the ovary and the uterus. Diagnosis of this type of tumour either as a separate independent primary or as a metastatic tumour is difficult. A careful consideration of a number of gross, histological and immuno- histochemical features may be helpful in the distinction between metastatic and synchronous primary tumours which have different therapeutic and prognostic implications [1, 2].
    [Show full text]
  • Non-Hodgkin's Lymphomas Involving the Uterus
    Non-Hodgkin’s Lymphomas Involving the Uterus: A Clinicopathologic Analysis of 26 Cases Russell Vang, M.D., L. Jeffrey Medeiros, M.D., Chul S. Ha, M.D., Michael Deavers, M.D. Department of Pathology, The University of Texas–Houston Medical School (RV), and the Departments of Pathology (LJM, MD) and Radiation Oncology (CSH), The University of Texas–M.D. Anderson Cancer Center, Houston, Texas KEY WORDS: B-cell, Immunohistochemistry, Non- Non-Hodgkin’s lymphomas (NHL) involving the Hodgkin’s lymphoma, Uterus. uterus may be either low-stage neoplasms that Mod Pathol 2000;13(1):19–28 probably arise in the uterus (primary) or systemic neoplasms with secondary involvement. In this Non-Hodgkin’s lymphoma (NHL) can involve ex- study, 26 NHL involving the uterus are reported. tranodal sites. Common extranodal locations in- Ten cases were stage IE or IIE and are presumed to clude the gastrointestinal tract and skin; however, be primary. The mean age of patients at presenta- the female reproductive system also may be af- tion was 55 years (range, 35 to 67 years), and abnor- fected, most commonly the ovary. Infrequently, mal uterine bleeding was the most frequent com- NHL may involve the uterus. Numerous studies of plaint (six patients). Nine of 10 tumors involved the NHL involving the uterus have been reported in the cervix. Histologically, eight were diffuse large B-cell literature, and we have identified at least 15 case lymphoma (DLBCL); one was follicle center lym- series that describe three or more patients (1–16). phoma, follicular, grade 1; and one was marginal However, in most of these studies, clinical zone B-cell lymphoma.
    [Show full text]
  • Abnormal Uterine Bleeding (AUB): an Uncommon Presentation of Ovarian Cancer
    Abnormal Uterine Bleeding (AUB): an uncommon presentation of ovarian cancer Mariana López 1, Georgina Blanco 1, Jimena Lange 2, Adriana Bermudez 2, Eugenia Lamas Majek 1, Florencia García Kammermann 3, Lucía Cardinal 3, Claudia Onetto 1, Carolina Milito 1, Silvio Tatti 4, Susana Leiderman 1 1 Gynecologic Endocrinology Unit, Gynecology Division. Buenos Aires University Hospital; 2 Gynecologic Oncology Unit, Gynecology Division. Buenos Aires University Hospital; 3 Gynecologic Pathology Division, Pathology Department. Buenos Aires University Hospital; 4 Gynecology Division. Buenos Aires University Hospital ABSTRACT Ovarian cancer usually presents with nonspecific symptoms, such as pelvic or abdominal discomfort. Abnormal uterine bleeding (AUB) is a very infrequent symptom of this neoplasm. Postmenopausal AUB can be due to steroid production by ovarian or adrenal tumors. We report the case of a postmenopausal 75-year-old patient who presented AUB. Blood tests showed high steroid lev- els (estrogens and androgens) and high CA-125 levels. Ultrasound showed a pelvic tumor, uterine myomatosis and an endometrial polyp. The patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy. The pathological examina- tion of the surgical specimen revealed a clear cell carcinoma in the right ovary with areas of adenofibroma. The patient is being followed up by our Gynecologic Oncology Unit. KEYWORDS AUB, ovarian cancer, hyperandrogenism, hyperestrogenism. Introduction Article history Received 7 Apr 2020 – Accepted 6 Jun 2020 Abnormal uterine bleeding (AUB) occurs in approximately Contact 5% of postmenopausal women. Since 7 to 9% of AUB cases Mariana López; [email protected] are due to endometrial cancer, the primary aim of the evalu- Gynecologic Endocrinology Unit, Gynecology Division ation in all post-menopausal women with AUB is to exclude Córdoba 2351 (C1120) Buenos Aires, Argentina malignancy [1,2].
    [Show full text]
  • Pelvic Pain and Adnexal Mass: Be Aware of Accessory and Cavitated Uterine Mass
    Hindawi Case Reports in Medicine Volume 2021, Article ID 6649663, 6 pages https://doi.org/10.1155/2021/6649663 Case Report Pelvic Pain and Adnexal Mass: Be Aware of Accessory and Cavitated Uterine Mass Pooya Iranpour ,1 Sara Haseli ,1,2 Pedram Keshavarz ,3 Amirreza Dehghanian ,4 and Neda Khalili 5 1Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran 3Department of Diagnostic & Interventional Radiology of New Hospitals LTD, Tbilisi, Georgia 4Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran 5School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Correspondence should be addressed to Sara Haseli; [email protected] Received 24 November 2020; Revised 19 January 2021; Accepted 30 January 2021; Published 11 February 2021 Academic Editor: Michael S. Firstenberg Copyright © 2021 Pooya Iranpour et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Accessory and cavitated uterine mass (ACUM) is a rare form of Mullerian anomaly that usually presents in young females with chronic cyclic pelvic pain and/or dysmenorrhea. +is clinical entity is often underdiagnosed as it may be mistaken for other differential diagnoses, such as pedunculated myoma or adnexal lesions. Imaging modalities, including ultrasonography and magnetic resonance imaging (MRI), accompanied with relevant and suspicious clinical findings are important tools in making acorrect diagnosis. To date, surgical excision of the mass remains the mainstay of treatment,which provides significant symptom relief.
    [Show full text]
  • Primary Ovarian Choriocarcinoma Mimicking Ectopic Pregnancy
    Case Report Obstet Gynecol Sci 2014;57(4):330-333 http://dx.doi.org/10.5468/ogs.2014.57.4.330 pISSN 2287-8572 · eISSN 2287-8580 Primary ovarian choriocarcinoma mimicking ectopic pregnancy Eun Jin Heo, Chel Hun Choi, Jung Min Park, Jeong-Won Lee, Duk-Soo Bae, Byoung-Gie Kim Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Nongestational ovarian choriocarcinoma is an exceedingly rare and highly aggressive tumor. Although early diagnosis and timely initiation of therapy is important, it is difficult in reproductive aged patients because of the frequent elevation of human chorionic gonadotropin. We report a primarily nongestational ovarian choriocarcinoma in a 12-year-old virgin female. Initial diagnosis based on abdominopelvic computed tomography and pelvis magnetic resonance imaging was ectopic pregnancy with hemoperitoneum. A diagnostic laparoscopy of the ovarian tumor revealed choriocarcinoma. Unilateral salpingo-oophorectomy and omental sampling revealed surgical stage of IA. Six courses of adjuvant combination chemotherapy (bleomycin, etoposide, and cisplatin) followed surgery. Keywords: Choriocarcinoma; Laparoscopy; Nongestational; Ovary Introduction nancy, which was finally diagnosed as nongestational ovarian choriocarcinoma. The patient was managed with laparoscopic Ovarian choriocarcinoma is a rare and highly aggressive tumor. ipsilateral salpingo-oophorectomy and surgical staging, fol- It may develop as a metastatic gestational choriocarcinoma lowed by the administration of combination chemotherapy. from uterus or tubal choriocarcinoma, as a primary gestation- al choriocarcinoma associated with ovarian pregnancy, or as a nongestational germ cell tumor differentiating towards the Case report trophoblastic structures [1]. The gestational type is more com- mon than the nongestational type; the estimated incidence of A 12-year-old virgin woman presented with a 20-day history a primary ovarian choriocarcinoma is 1 in 389,000,000.
    [Show full text]
  • The Uterus and the Endometrium Common and Unusual Pathologies
    The uterus and the endometrium Common and unusual pathologies Dr Anne Marie Coady Consultant Radiologist Head of Obstetric and Gynaecological Ultrasound HEY WACH Lecture outline Normal • Unusual Pathologies • Definitions – Asherman’s – Flexion – Osseous metaplasia – Version – Post ablation syndrome • Normal appearances – Uterus • Not covering congenital uterine – Cervix malformations • Dimensions Pathologies • Uterine – Adenomyosis – Fibroids • Endometrial – Polyps – Hyperplasia – Cancer To be avoided at all costs • Do not describe every uterus with two endometrial cavities as a bicornuate uterus • Do not use “malignancy cannot be excluded” as a blanket term to describe a mass that you cannot categorize • Do not use “ectopic cannot be excluded” just because you cannot determine the site of the pregnancy 2 Endometrial cavities Lecture outline • Definitions • Unusual Pathologies – Flexion – Asherman’s – Version – Osseous metaplasia • Normal appearances – Post ablation syndrome – Uterus – Cervix • Not covering congenital uterine • Dimensions malformations • Pathologies • Uterine – Adenomyosis – Fibroids • Endometrial – Polyps – Hyperplasia – Cancer Anteflexed Definitions 2 terms are described to the orientation of the uterus in the pelvis Flexion Version Flexion is the bending of the uterus on itself and the angle that the uterus makes in the mid sagittal plane with the cervix i.e. the angle between the isthmus: cervix/lower segment and the fundus Anteflexed < 180 degrees Retroflexed > 180 degrees Retroflexed Definitions 2 terms are described
    [Show full text]